Nadia Harbeck

Nadia Harbeck is a leading expert in neoadjuvant and adjuvant therapy for HER2-positive and triple-negative breast cancer and has co-authored landmark European guidelines for early breast cancer. She has contributed to multiple pivotal neoadjuvant HER2+ trials examining dual HER2 blockade and de-escalation strategies. Her work has shaped European and international guidelines for neoadjuvant breast cancer therapy and she serves as AGO Breast Committee chair. Harbeck advocates evidence-based integration of pCR data with long-term outcomes for treatment decision making.